Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Swiss biotechnology company Mymetics has released the preclinical trial results of its innovative HIV-1 (Human Immunodeficiency Virus type 1) vaccine.
Subscribe to our email newsletter
The small-scale study on Chinese macaques was conducted by Mymetics at the Institute of Laboratory Animal Science (ILAS) in Beijing in collaboration with Cochin Institute and INSERM, Paris scientist Morgane Bomsel.
Results demonstrated 100% protection in one arm of the study against multiple intra-vaginal challenges with heterologous live virus.
An in vitro assay showcased a correlation between protection and the induction of mucosal antibodies capable of blocking the passage of HIV-1 across a cell monolayer.
Protected animals had blood IgG antibodies but these lacked virus-neutralizing activity.
These results were found to be unprecedented for this sort of HIV-1 vaccine study, and confirm the importance of non-neutralizing antibodies to prevent HIV-1 transmission and early infection events, Mymetics said.
Mymetics and Swiss vaccine company Pevion Biotech co-developed the HIV-1 vaccine using proprietary virosome technology, and Px-Therapeutics.
Mymetics now aims to use its vaccine to provide both a first line of defense through mucosal protection, and a second line of defense against infection through blood antibody generation.